Farmitalia Carlo Erba subsidiary signs letter of intent to acquire Ellem S.p.A., another Italian pharmaceutical company. Ellem, Erbamont reports, has "one primary product on the market, leucotrophine, a thymus extract, which is a proprietary immunostimulating compound." Ellem also has several other products in the immunology area under development.
You may also be interested in...
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.
A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.